PSGR interviewed Dr David Bell as his experience encompasses biotech drug development & public health. You can also listen on Spotify at @PSGRNZ.
The current Gene Technology Bill deregulates gene editing technologies and gene edited organisms, so they don’t have to be declared, won’t be monitored and won’t be tracked or labelled. Is this risk worth it for the financial outcome?
But is the government deregulating and making big investments in biotech for ‘health’ and ‘climate change’ - good value for New Zealand’s money?
Dr David Bell, is a public health physician and biotech consultant in global health.
David has a position as co-lead of the University of Leeds REPPARE project on pandemics, and is a senior scholar at Brownstone Institute.
David is a former medical officer and scientist at the World Health Organization (WHO), Programme Head for malaria and febrile diseases at the Foundation for Innovative New Diagnostics (FIND) in Geneva, Switzerland, and Director of Global Health Technologies at Intellectual Ventures Global Good Fund in Bellevue, WA, USA.
You can follow David on social media at X.
A 20-year shift from organisations that invest in medical development to improve global health (and break even), to going for gold - the big profits.
A WHO that is dependent on earmarked funding - ‘a gun for hire’.
The turn away from the fundamentals - nutrition and sanitation.
Perverse incentives: When governments merge with business for profit.
NZ’ Gene Technology Bill has a medical mandate obligating the regulator to approve a foreign gene therapy immediately.
Covid-19 as a case study. The dubious origins, the distortion of population-level risk, the failure to adopt safer therapeutic treatments.
Organisations inflating risk profiles of pandemics in order to secure a social license for global acceptance of a vaccine.
Risk from communicable diseases that require good nutrition, but have no drug solutions are played down, even though they may be causing greater global harm.
A recent REPPARE analysis of a key report on inflated pandemic risk by Metabiota – Gingko Bioworks. It was one of two main sources for concluding a rapidly rising risk in the G20 High Level Independent Panel (HLIP) report in June 2021, which was influential in informing G20 Group of Nations support for WHO’s PPPR agenda.
Failure of governments to disclose the Pfizer contract ‘they’re buying a product.’
Good nutrition as better bang for government’s buck for infectious disease & non-communicable (chronic) disease.
An opinion on Larry Ellison’s use of AI to detect and build genetic vaccines.
When models and reality clash. October 2024. Report prepared for the New Zealand Royal Commission on COVID-19 Lessons Learned by Re-Evaluating the Pandemic Preparedness And REsponse agenda (REPPARE) research group, University of Leeds, United Kingdom.
If you’re interested in the Gene Tech Bill, have you listened to our other recent podcast (on Substack or Spotify; or watched the video) with Professor Jack Heinemann, Director of Centre for Integrated Research in Biosafety (INBI) & PhD candidates who joined other coauthors in drafting INBI’s submission to New Zealand’s Gene Technology Bill?
9 days left to send in your submission:
Share this post